Article Figures & Data
Figures
- FIGURE 1.
Changes in 18F-DCFPyL PET/CT imaging after 3 mo of BAT. Baseline and follow-up maximum-intensity-projection whole-body images are shown for each patient included in study. For patients 4–6, representative new lesions or sites of progression are demarcated with arrows. Additional new lesions may be hidden by normal uptake or other sites of disease.
- FIGURE 2.
Swimmer plot showing radiographic response/progression on BAT. All patients were followed until radiographic progression. 18F-DCFPyL PET/CT imaging was performed before start of BAT and after 3 mo of treatment. Patients 1–3 had no progression noted with 18F-DCFPyL. Patients 4–6 had new 18F-DCFPyL–avid lesions. These data suggest that disease progression on PSMA-targeted PET imaging precedes detection on conventional imaging.
Tables
Patient PSA change Tumor change PSMA result 1 93% Not evaluable No progression 2 −98% −44% No progression 3 −93% −23% No progression 4 1% −11% Progression 5 −55% −2% Progression 6 −63% −25% Progression
Supplemental Data
Files in this Data Supplement:
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.